Mainz Biomed B.V. (MYNZ) Stock Analysis & Investment Frameworks
Mainz Biomed B.V. (MYNZ) stock analysis on Invetso. Review Mainz Biomed B.V.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Mainz Biomed B.V. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: DE
Mainz Biomed B.V. Key Financial Metrics
- Market Cap: $14.69M
- Revenue: $537080.00
- ROE: -179.80%
- ROIC: -75.12%
- Dividend Yield: N/A
About Mainz Biomed B.V.
Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for detecting colorectal cancer. Additionally, they are developing PancAlert, a promising product candidate intended for pancreatic cancer screening. Beyond cancer, Mainz Biomed also provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments. Established in 2008, the company maintains its headquarters in Mainz, Germany.
Mainz Biomed B.V. Investment Frameworks
Invetso analyzes Mainz Biomed B.V. (MYNZ) across the following frameworks:
- Mainz Biomed B.V. 10Y Growth Potential
- Mainz Biomed B.V. Scenario Analysis
- Mainz Biomed B.V. Risks & Opportunities
- Mainz Biomed B.V. Economic Moat
- Mainz Biomed B.V. Business Model
- Mainz Biomed B.V. Management
- Mainz Biomed B.V. SWOT Analysis
- Mainz Biomed B.V. Porter's 5 Forces
- Mainz Biomed B.V. PESTLE Analysis
- Mainz Biomed B.V. ESG Analysis